Repligen Launches Trial of Imaging Agent

Repligen (NASDAQ: [[ticker:RGEN]]) of Waltham, MA, has begun a Phase 3 clinical trial of an imaging agent that would enhance the ability of magnetic resonance imaging (MRI) to detect abnormalities in the ducts of the pancreas, the company announced today. The company believes that the study, being conducted at about 30 U.S. and Canadian sites, could provide enough data to warrant approval of the agent, which is a synthetic version of the hormone secretin. The agent could potentially be used during some 150,000 pancreatic scans in the U.S. each year, according to Repligen.

Author: Rebecca Zacks

Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University. View all posts by Rebecca Zacks